European journal of hospital pharmacy : science and practice最新文献

{"title":"When excipients matter: cyclodextrins, renal impairment and intravenous drug therapy.","authors":"Silvia Vázquez-Gómez, Sandra Caíña López","doi":"10.1136/ejhpharm-2026-005390","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-005390","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the clinical impact of carbapenem pre-authorisation on clinical outcomes in a setting with a high prevalence of extended-spectrum beta-lactamase producing organisms: a focus on the Middle East.","authors":"Amna Nauman, Wasim S El Nekidy, Emna Abidi, Rania El Lababidi","doi":"10.1136/ejhpharm-2026-004967","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-004967","url":null,"abstract":"<p><strong>Background: </strong>Data on carbapenem pre-authorisation in hospitals with a high prevalence of extended-spectrum β-lactamase (ESBL) producing organisms is scarce. Therefore, the aim of this study was to evaluate the impact of implementing a carbapenem pre-authorisation policy on patients admitted to our acute care floors, focusing on appropriateness of use and the clinical outcomes.</p><p><strong>Methods: </strong>A retrospective observational quasi-experimental study was conducted comparing data from adults with active infections admitted to the acute care floors during the pre-restriction period (December 2021-May 2022) and the post-restriction period (June 2022-December 2023) who were prescribed carbapenems (ertapenem or meropenem).</p><p><strong>Results: </strong>A total of 244 patients met the inclusion criteria, with 131 in the pre-implementation period and 113 in the post-implementation period. The proportion of appropriately indicated carbapenem use was significantly higher in the post-restriction group at 69.9% (79) compared with 55.7% (73) in the pre-restriction group (p=0.025). The 30-day all-cause mortality rate was significantly lower in the post-restriction group at 8 (7.1%) vs 26 (19.8%) in the pre-restriction group (p=0.005). Length of hospital stay was also significantly reduced in the post-restriction group, with a median of 6 days compared with 9 days in the pre-restriction group (p=0.002). Additionally, the 30-day readmission rate was lower in the post-restriction group at 20.4% (23) compared with 32.1% (42) in the pre-restriction group (p=0.043). The multivariate logistic regression analysis indicated that the quick Sequential Organ Failure Assessment (qSOFA) score was the only independent risk factor for mortality (OR 3.2; 95% CI 1.3 to 7.9; p = 0.013), while neither the carbapenem used nor the restriction policy demonstrated a significant association with mortality.</p><p><strong>Conclusion: </strong>Despite the high prevalence of ESBL-producing organisms, the carbapenem pre-authorisation policy proved effective in optimising their use, particularly with respect to appropriateness and clinical outcomes. Larger studies are warranted to corroborate these findings.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"We love big numbers-in most cases!","authors":"Philip Wiffen","doi":"10.1136/ejhpharm-2026-005380","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-005380","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From limited options to therapeutic innovation: the changing landscape of transthyretin amyloidosis.","authors":"Silvia Vázquez-Gómez, Sandra Caíña López","doi":"10.1136/ejhpharm-2026-005372","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-005372","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond efficacy and cost: should environmental impact become part of hospital pharmacy decision-making?","authors":"Aron Misa Garcia, Sara Ferro Rodríguez","doi":"10.1136/ejhpharm-2026-005351","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-005351","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Think twice before labelling 'drug allergy': a case report.","authors":"Yasemin Akgul Balaban, Mustafa İlker İnan, Fevzi Demirel","doi":"10.1136/ejhpharm-2025-004840","DOIUrl":"https://doi.org/10.1136/ejhpharm-2025-004840","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excreta contamination after antibody-drug conjugates administration: a systematic review and guidance for hospital pharmacists.","authors":"Roland B van den Berg, Sophie Bonte, Kelly L Niggebrugge-Mentink, Christina W Swart, Eleonora L Swart, Mirjam Crul","doi":"10.1136/ejhpharm-2026-005172","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-005172","url":null,"abstract":"<p><p>Antibody-drug conjugates (ADCs) are increasingly used in oncology practice, yet guidance is lacking regarding the safe handling of patient excreta after administration. As ADCs contain cytotoxic payloads and active metabolites that may be excreted via urine or faeces, evidence-based recommendations are required to support hospital pharmacists in the development of guidelines for the safe handling of excreta from patients treated with these hazardous drugs. Therefore, this review aimed to evaluate the available evidence on ADC excretion and to develop practical recommendations for precautionary handling periods. A systematic literature search of three databases (PubMed, Scopus, and Embase) was performed to identify human and preclinical studies reporting excretion or mass balance data for approved ADCs. Two pharmacists independently screened studies and extracted relevant data. Evidence was summarised descriptively. Practical precautionary periods were developed by consensus among the authors. For ADCs without published mass balance data, conservative estimates were calculated using seven terminal half-lives reported in the Summary of Product Characteristics. Of 328 unique records identified, six studies met the inclusion criteria and included data on five ADCs. Available evidence demonstrated predominantly biliary/faecal excretion of cytotoxic payload-related compounds, with limited urinary elimination. In most studies, more than 80% of the administered dose was recovered within 14 days. Based on available evidence and pharmacokinetic estimates, recommended precautionary handling periods for patient excreta ranged from 5 to 144 days across currently authorised ADCs. This review provides a practical overview of available ADC excretion data relevant for hospital pharmacists and healthcare professionals in oncology. The proposed precautionary periods may support hospital pharmacists in the development of local handling procedures and contribute to safer management of patient excreta by nurses and other healthcare professionals involved in oncology care.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct writing on intravenous bags: convenience versus uncertain compatibility.","authors":"Silvia Vázquez-Gómez, Sandra Caíña López","doi":"10.1136/ejhpharm-2026-005331","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-005331","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the organisation, operation and inquiries of Centres for Medicines Information: insights from a narrative review and questionnaire.","authors":"Evelyne Van den Broucke, Ming Min, Lien Cosemans, Pieter-Jan Cortoos, Thomas De Rijdt, Frank Weekers, Charlotte Quintens, Isabel Spriet","doi":"10.1136/ejhpharm-2025-004701","DOIUrl":"https://doi.org/10.1136/ejhpharm-2025-004701","url":null,"abstract":"<p><strong>Objectives: </strong>Centres for Medicines Information (CMIs) are core components in providing evidence-based recommendations to practitioners, thus reducing medication errors. This study examined the organisational and operational features of international CMIs and the types of inquiries they address. Its findings aim to support the development of new CMIs and to suggest recommendations for improvement.</p><p><strong>Methods: </strong>A narrative review was conducted using PubMed as the database. In addition, an anonymous e-questionnaire was sent to hospital pharmacists through the European Association of Hospital Pharmacists.</p><p><strong>Results: </strong>Findings from 20 studies and surveys from seven CMIs showed that most were hospital-based. The literature suggested that they provided regional services while survey data indicated they typically served a single institution. They mostly operated during regular working hours, with some offering 24/7 availability. CMIs primarily supported healthcare professionals by addressing medication-related queries. However, proactive information dissemination via newsletters and education is also important, as well as promoting the service. Digital documentation was more common in newer CMIs, while older ones lacked such integration. The use of Frequently Asked Question pages was limited across all CMIs. Electronic health record-based inquiry systems were rare, found in only three hospitals surveyed. Pharmacists were the main personnel, although the levels of training varied. To ensure effectiveness, quality assurance efforts focused on documenting references and responses, validating answers and ensuring timely replies.</p><p><strong>Conclusion: </strong>This study offers an overview of CMIs, aiming to guide their organisation and practice. The findings suggest that future CMIs should prioritise regional collaboration and digital integration to boost efficiency and cost-effectiveness.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administrative delays in access to high-impact medicines: a patient safety risk.","authors":"Silvia Vázquez-Gómez, Débora Feijoo-Meléndez, Sandra Caíña López","doi":"10.1136/ejhpharm-2026-005309","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-005309","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}